Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gossamer Bio Inc (GOSS)
NASDAQ:GOSS
GOSS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.50 - $1.60
Previous CloseN/A
Volume602.63K
Average Volume (3M)1.33M
Market Cap
$346.70M
Enterprise Value$99.86M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.61
Next Earnings
Mar 21, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding226,604,140
10 Day Avg. Volume2,129,170
30 Day Avg. Volume1,328,290
Standard Deviation0.24
R-Squared0.16
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.06
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-22.77
Enterprise Value/Ebitda-1.76
Forecast
1Y Price Target
$8.00Price Target Upside471.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Gossamer Bio News
---
Bulls Say, Bears Say
Bulls Say
Collaborative OpportunitiesThe strategic collaboration with Chiesi for the co-development and commercialization of seralutinib in PAH and PH-ILD further validates the potential of the program and strengthens its financial position.
Efficacy In PAHThe 72-week data support seralutinib's long-term efficacy profile in PAH, showing continued improvement in clinical outcome measures with seralutinib treatment.
Market ExpansionUpcoming expansion into PH-ILD may unlock blockbuster potential, in the view of the management.
Bears Say
Development ChallengesA global registrational Phase 3 program evaluating seralutinib in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) is expected to start in mid-2025, pending discussions with regulators, further validating the program, in our view.
Financial PerformanceGOSS reported a net loss of $30.8M, indicating financial challenges despite having $327M in cash.
Investor ExpectationsGOSS reported Phase 2 week 24 topline data that fell below investor expectations on the magnitude of PVR/6MWD change.
---
Ownership Overview
9.40% Insiders
10.24% Mutual Funds
45.52% Other Institutional Investors
28.83% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GOSS FAQ
What was Gossamer Bio Inc’s price range in the past 12 months?
Gossamer Bio Inc lowest stock price was $0.50 and its highest was $1.60 in the past 12 months.
What is Gossamer Bio Inc’s market cap?
Gossamer Bio Inc’s market cap is $346.70M.
When is Gossamer Bio Inc’s upcoming earnings report date?
Gossamer Bio Inc’s upcoming earnings report date is Mar 21, 2025 which is in 27 days.
How were Gossamer Bio Inc’s earnings last quarter?
Gossamer Bio Inc released its earnings results on Nov 07, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.147 by $0.007.
Is Gossamer Bio Inc overvalued?
According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued.
Does Gossamer Bio Inc pay dividends?
Gossamer Bio Inc does not currently pay dividends.
What is Gossamer Bio Inc’s EPS estimate?
Gossamer Bio Inc’s EPS estimate is -0.17.
How many shares outstanding does Gossamer Bio Inc have?
Gossamer Bio Inc has 226,604,140 shares outstanding.
What happened to Gossamer Bio Inc’s price movement after its last earnings report?
Gossamer Bio Inc reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.147. Following the earnings report the stock price went down -1.124%.
Which hedge fund is a major shareholder of Gossamer Bio Inc?
Currently, no hedge funds are holding shares in GOSS
---
Gossamer Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (471.43% Upside)
$8.00 (471.43% Upside)
Blogger Sentiment
Bullish
GOSS Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.42%
12-Months-Change
Fundamentals
Return on Equity
-90.26%
Trailing 12-Months
Asset Growth
0.85%
Trailing 12-Months
Company Description
Gossamer Bio Inc
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
---
GOSS Stock 12 Month Forecast
Average Price Target
$8.00
▲(471.43% Upside)
Technical Analysis
Best Analysts Covering GOSS
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
-10.44%
assigned a buy rating 5 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -10.44% per trade.
---